Promising methods of treatment of the syndrome of senile fragility: focus on mesenchymal stem cells

ABSTRACT. Senile frailty syndrome (SFS) develops in the elderly and senile as a result of aging-related degeneration and manifests itself in decreased psychological, physiological, and social functioning. Despite decades of research that have led to a growing understanding of the biological changes in SFS, there is currently no approved medical strategy that can effectively attenuate or reverse senile frailty. Mesenchymal stem cell (MSC) therapy is one of the promising methods of treating SFS. The presented review analyzes the capabilities of MSCs in the treatment of the SFS and its complications. It has been shown that the high clinical effectiveness and safety of the use of MSCs has been confirmed in the treatment of many diseases and pathological conditions, especially in elderly people with SFS.